Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent and Consolidative Durvalumab with Radiotherapy for Stage III NSCLC
NCT04003246Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2020
- Primary completion
- Jun 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by UT Southwestern Medical Center. Started Apr 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04003246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003246.